Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Elotuzumab with Car/Pom/Dex for high-risk R/R myeloma

James Berenson • 14 Sep 2019
IMW 2019
Multiple Myeloma Antibodies Carfilzomib Dexamethasone Elotuzumab Pomalidomide

Here, James Berenson, MD, from The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, discusses the Phase II study (NCT0310427) of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for patients with high-risk R/R myeloma. Dr Berenson was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from James Berenson

1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
1:08
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals